Last Update: Apr 05, 2024
A Randomized, Two-arm, Placebo-controlled, Participant, Investigator and Sponsor-blinded, Proof-of-concept Study Investigating the Efficacy, Safety and Tolerability of QUC398 in Patients With Symptomatic Knee Osteoarthritis
ClinicalTrials.gov Identifier:
Novartis Reference Number:CQUC398A12201
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

The purpose of the study is to find out if the investigational treatment named QUC398 has beneficial effects on osteoarthritis knee pain and knee cartilage, and if it is safe and well tolerated.

This is a phase IIa study to establish the effect of QUC398 on pain and cartilage preservation in participants with symptomatic knee OA

Osteoarthritis, Knee
Phase 2
Recruiting
98
Nov 09, 2022
Oct 06, 2025
All
40 Years - 80 Years (Adult, Older Adult)

Interventions

Drug

Placebo

Placebo 0 mg/mL, solution for s.c. injection (1 mL)
Drug

QUC398

QUC398 150 mg/mL, solution for s.c. injection (1 mL)

Eligibility Criteria

Inclusion Criteria:

Weight ≥ 50 kg and body mass index 18 -35 kg/m2 at Screening 1
Kellgren-Lawrence grade 2 to 4 in the tibio-femoral compartment in the target knee confirmed by radiography in standing weight-bearing fixed flexion position and posterior-anterior view, at Screening 1
mJSN 1-2 in the medial tibiofemoral compartment of the target knee, confirmed with Xray by central reader at Screening 1
Symptomatic OA with moderate to severe pain (corresponding to Pain NRS ≥ 5 to ≤ 9) in the target knee for the majority of days in the last 3 months prior to Screening 1, as per participant's judgement

Symptomatic OA with moderate to severe pain (corresponding to Pain NRS ≥ 5 to ≤ 9) in the target knee at Screening 1 and 2

. Moderate to severe OA pain (corresponding to Pain NRS ≥5 to ≤9) in the target knee during the last 7 days prior to Screening 3, confirmed by: Completed pain diary for at least 6 of the last 7 days prior to Screening 3, AND Diary reported Pain NRS ≥5 to ≤9 for at least 6 of the last 7 days prior to Screening 3

KOOS pain subscale ≤ 60 in the target knee at Screening 1, Screening 2, and Screening 3

Exclusion Criteria:

Painful ipsilateral hip OA defined as a Pain NRS ≥3 on the majority of days in the last 3 months prior to Screening 1, as reported by the patient
Symptomatic, patello-femoral pain in the target knee as per investigator's examination at Screening 1
Severe malalignment > 7.5º in the target knee (either varus or valgus), measured using standardized knee X-ray at Screening 1
Patient unable or unwilling to undergo MRI or presenting absolute contraindications to MRI
Previous exposure to any ADAMTS-5 drug, including QUC398.
History or current diagnosis of ECG abnormalities

Other protocol-defined inclusion/exclusion criteria may apply

Study Location

Novartis Investigative Site

Recruiting

Southport,Queensland,4222,Australia

Novartis Investigative Site

Recruiting

St Leonards,New South Wales,2065,Australia

Novartis Investigative Site

Recruiting

Christchurch,8011,Australia

Novartis Investigative Site

Recruiting

Vejle,7100,Denmark

Novartis Investigative Site

Recruiting

Herlev,2730,Denmark

Novartis Investigative Site

Recruiting

Nice,Cedex1,06001,France

Novartis Investigative Site

Recruiting

Orleans,45100,France

Novartis Investigative Site

Recruiting

Paris,75012,France

Novartis Investigative Site

Recruiting

Sevilla,41010,Spain

Novartis Investigative Site

Recruiting

La Coruna,Galicia,15006,Spain

Novartis Investigative Site

Recruiting

Leganes,Madrid,28915,Spain

Novartis Investigative Site

Recruiting

Barcelona,Cataluna,08022,Spain

Novartis Investigative Site

Recruiting

Sabadell,Barcelona,08208,Spain

Boston Univ School Of Medicine .

Recruiting

Boston,Rutvi Patel email: [email protected] -- Tuhina Neogi,02118 - Massachusetts,United States

Clinical Research of West FL Inc. .

Recruiting

Tampa,Rachel Matthews (813-870-1292) email: [email protected] -- Paul A Lunseth,33603 - Florida,United States

CoastalOrthoandSportsMedofSWFlorida .

Recruiting

Bradenton,Caitlin Towsley (941-792-1404) email: [email protected] -- David Cashen,34209 - Florida,United States

Meridien Research

Recruiting

Maitland,Lindsay Theisen (407-644-1165) email: [email protected] -- Eva Maria Heurich,32751 - Florida,United States

West Clinical Research Private Clinic

Recruiting

Morehead City,Millicent Clark email: [email protected] -- Jeffrey K Moore,28557 - North Carolina,United States

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals

Novartis Pharmaceuticals